Intelligence » MRSA » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    Destiny Pharma's XF-73 MRSA drug gets FDA fast track designation

    Friday, March 16, 2018 -- Destiny Pharma’s has secured fast track designation from the US Food and Drug Administration (FDA) for its lead clinical candidate exeporfinium chloride (XF-73) for the prevention of post-surgical staphylococcal infections such as Methicillin Resistant Staphylococcus aureus (MRSA).